Using an automated PCR-based genomics approach, TOtal Gene expression Analysis (TOGA s ), we have examined gene expression profiles of mouse striatum and frontal cortex in response to clozapine and haloperidol drug treatment. Of 17 315 mRNAs observed, TOGA s identified several groups of related molecules that were regulated by drug treatment. The expression of some genes encoding proteins involved in neurotransmission, signal transduction, oxidative stress, cell adhesion, apoptosis and proteolysis were altered in the brains of both clozapine-and haloperidol-treated mice as recognized by TOGA s . Most notable was the differential expression of those genes whose products are associated with lipid metabolism. These include apolipoprotein D (apoD), the mouse homolog of oxysterol-binding protein-like protein 8 (OSBPL8), a diacylglycerol receptor (n-chimerin), and lysophosphatidic acid (LPA) acyltransferase. Real-time PCR analysis confirmed increases in the RNA expression of apoD (1.6-2.2-fold) and OSBPL8 (1.7-2.6-fold), and decreases in the RNA expression of nchimerin (1.5-2.2-fold) and LPA acyltransferase (1.5-fold) in response to haloperidol and/or clozapine treatment. Additional molecules related to calcium homeostasis and signal transduction, as well as four sequences of previously unidentified mRNAs, were also confirmed by real-time PCR to be regulated by drug treatment. While antipsychotic drugs may affect several metabolic pathways, lipid metabolism/signaling pathways may be of particular importance in the mechanisms of antipsychotic drug action and in the pathophysiology of psychiatric disorders. Molecular Psychiatry (2003) 8, 983-993.
Introduction
Neuropsychiatric disorders, including schizophrenia and bipolar disorder, are a heterogeneous group of devastating illnesses affecting 1-2% of people worldwide. Psychosis is a symptom in many psychiatric illnesses, while specific symptoms of schizophrenia include a diversity of both 'positive' symptoms, such as delusions, hallucinations, disordered thinking and bizarre behavior, and 'negative' symptoms, such as social withdrawal, affective blunting, alogia (absence of words) and anhedonia (decrease in the ability to experience pleasure). 1 Most symptoms are treatable by the administration of antipsychotic drugs. The efficacy of such medications has been well established in that antipsychotic drugs reduce symptomatology and prevent relapse in a large percentage of patients. The two main classes of drugs are the 'typical' and 'atypical' antipsychotics. Typical antipsychotic drugs, which include haloperidol, chlorpromazine and fluphenazine, are primarily dopamine D 2 receptor antagonists, while the 'atypical' antipsychotics, such as clozapine, risperidone and olanzapine, have a range of affinities for several different neurotransmitter receptors in addition to those for dopamine. [2] [3] [4] The major existing theories of psychiatric diseases have been developed by exploring the mechanisms of action of these antipsychotic drugs. For example, the 'dopamine hypothesis' of schizophrenia, formulated over 30 years ago, proposes that the hyperactivity of dopaminergic neurotransmission causes symptoms of schizophrenia. 5, 6 Major support for this hypothesis comes from indirect pharmacological evidence, that is, the excellent correlation observed between the clinical efficacy of typical antipsychotic drugs and their binding to the dopamine D 2 receptor. 7, 8 Similarly, serotonergic systems have also been implicated in schizophrenia, largely because many of the newer atypical drugs have high affinity for the serotonin 2 class of receptors. 9, 10 There is a substantial body of evidence supporting neurotransmitter receptor abnormalities in psychiatric disorders, and this concept has successfully guided the development of drugs to treat these disorders. However, it has become clear that other, additional systems, components and/or factors are required to explain the complex nature of these diseases. Further examination of the mechanisms of antipsychotic drug action should reveal key information regarding the underlying pathophysiological features of psychiatric diseases and may lead to novel targets for drug treatment.
The administration of antipsychotic drugs has been shown to elicit changes in gene expression. Several studies have shown increases in the expression of immediate-early genes (IEGs) after acute drug exposure. [11] [12] [13] [14] [15] Many IEGs are known to act as transcriptional regulators, thereby linking receptor-mediated effects to changes in genomic activity. In addition, some studies have examined the expression of candidate genes in animals after chronic exposure to antipsychotic drugs. Alterations in the expression of neuropeptides, including preprotachykinin, preproenkephalin and neurotensin, have been found in response to haloperidol treatment, [16] [17] [18] [19] while chronic haloperidol and/or clozapine administration causes changes in the expression of nuclear receptors, 20 synaptic proteins 21 and various neurotransmitter receptors, most reproducibly components of the glutamatergic system. [22] [23] [24] [25] Two recent studies have used cDNA microarrays to investigate global changes in gene expression in response to drug treatment: one examining the effects of chronic haloperidol treatment on gene expression in rat striatum 26 and the other looking at the effects of acute clozapine treatment in the rat cortex. 27 The results from both studies have implicated synaptic function and calcium regulation as being important to the mechanisms of drug action.
In this study, we have surveyed gene expression changes in the mouse striatum and prefrontal cortex both after clozapine and after haloperidol administration, using the PCR-based, RNA display method, TOtal Gene expression Analysis (TOGA s ). We have identified several groups of molecules whose expression patterns are altered by drug treatment, most notably changes in the expression of genes related to phospholipids/fatty acid signaling/metabolism.
Materials and methods

Animal procedures and tissue preparation
Male C57BL/6J mice (20-28 g) were housed in groups of four on a standard 12/12 h light-dark cycle with ad libitum access to standard laboratory chow and tap water. Groups of mice were treated with clozapine, haloperidol or saline for different time points (n¼25 mice per drug per time point). For acute drug treatments, mice received a single intraperitoneal injection of saline or clozapine (7.5 mg/kg) and were killed by CO 2 inhalation after 45 min or 7 h. For chronic treatments, mice received daily subcutaneous injections of clozapine (7.5 mg/kg) or haloperidol (4 mg/kg) and were killed 24 h after their final injection at 5 days, 12 days or 2 weeks. The dose of haloperidol used was approximately the ED 50 for inducing catalepsy in the C57BL/6J strain, while that for clozapine was the same as that previously shown to interrupt cognitive function in mice and one-tenth that reported to induce catalepsy. 28 Brains were rapidly removed and placed on ice. The striatum and frontal cortex were dissected out and placed in ice-cold phosphate-buffered saline. These striata and cortical samples were pooled and the total and poly(A þ ) RNA were prepared according to Thomas et al, 29 and subjected to TOGA s and real-time PCR analyses. RNA was also prepared from the striata and cortex from a separate set of mice (n¼20/drug/time point) and used for Northern blot analysis.
TOGA
s data analysis and statistics Poly(A þ ) RNA from control and drug-treated animals were subjected to TOGA s methodology as described previously 30 and modified as described at www.dgt. com. All data analyses were performed using TOGA s proprietary software. To determine global variation in all data sets, correlations coefficients were determined by linear regression analysis of pairwise comparisons of normalized peak amplitudes. In the cortical samples, the lowest correlation coefficient was 0.971 among all samples, while the lowest correlation coefficient in the striatum samples was 0.942, which represented the correlation between the control and 2-week drug-treated time point, a comparison in which the greatest number of genes would be expected to be regulated, hence giving rise to the lower correlation coefficient. The software also calculated a variance histogram to describe the amount of gene variation within a given sample set. In this data set, 99.7% of all genes showed a variance less than 0.6. The remaining 0.3% of genes therefore represent drug-regulated genes or random variation. Using the criteria given below, we identified 51 genes out of 17 315 screened, which represents 0.29% of the genes.
All samples were run in duplicate and the average peak amplitude was used to determine fold regulation. Genes were determined to have regulated expression levels in the drug-treated samples vs the control groups based on the following criteria: (1) a Z1.6-fold change in the expression level between the average peak amplitude of a given cDNA in the drugtreated samples compared to controls; (2) each regulated cDNA must be consistently altered by Z1.6-fold in both chronic time points (12 days and 2 weeks) compared to both control time points and (3) each cDNA must have a threshold abundance value of Z75 arbitrary fluorescence units. All peaks below this value were considered to be background signal. Furthermore, all computer-generated picks were then manually screened to assess peak quality and integrity. cDNAs were eliminated when visual inspection suggested that they were spectral artifacts.
A two-tailed permutation argument was used to determine the significance of a drug effect on the regulation of cDNA levels. We partitioned the chronic drug time points and both control time points into every possible combination of two (representing the requirement for a given cDNA to be regulated in both chronic time points compared to both controls) and then determined how many of these partitions resulted in 'hits', where a 'hit' is Z1.6-fold change in the peak amplitude between partitioned sets. From these permutations, we could determine the significance of our observed number of hits due to drug treatment (the chronic time points relative to the controls) compared to the expected number of hits under the null hypothesis of no drug effect (ie every combination of time points producing an equal number of hits). The following formula describes the approximate standard normal random variable under these conditions:
where Obs is the observed number of hits we identified according to the above criteria; k is the total number of hits from every permutation of time points; n is the total number of genes visualized. In the above formula, p¼k/3n. We calculated P-values for different TOGA s fold changes (1.4-1.8-fold) and different threshold values (25-100 arbitrary fluorescence units), resulting in a range of P-values from 0.0003 to 0.0013, all indicating a significant effect of drug at these criteria.
Real-time PCR validation
Real-time PCR experiments were performed using the ABI PRISM s 7700 Sequence Detection System (Applied Biosystems), according to the manufacturer's guidelines with the SYBR Green Reagent as the fluorescent reporter molecule. PCR products were amplified from first-strand cDNA prepared from 1 mg polyA þ -selected RNA from the striatum of pooled control and drug-treated mice. This RNA was the same as that used in the initial TOGA s analysis. Primers specific to each cDNA were used in combination with primers to amplify housekeeping genes. The housekeeping gene, hypoxanthine:guanine phosphoribosyl transferase (HPRT), was used to normalize the expression levels in these studies. The absence of nonspecific amplification and the presence of a single PCR product are confirmed for each primer pair by agarose-gel electrophoresis. For the clozapine-regulated candidate genes, 68% of the cDNAs (11 out of 16) were validated by real-time PCR analysis.
Northern blot analysis
The total (15 mg/lane) and/or poly(A þ ) RNA (2 mg/ lane) were separated by electrophoresis and transferred onto Biotrans membrane using standard techniques.
Hybridization bands were quantified by densitometry. Data were normalized to cyclophilin hybridization and are expressed as fold stimulation over basal.
In situ hybridization analysis In situ hybridization was performed on free-floating sections from brains of control mice and those treated with saline, haloperidol (4 mg/kg) or clozapine (7.5 mg/kg) (n¼4 for each treatment) as described previously. 31 Coronal sections were hybridized at 551C for 16 h with a 35 S-labeled, single-stranded antisense cRNA probe against 12 different cDNA clones (10 7 cpm/ml).
35
S-labeled sense-strand probes were used as controls. Excess probe was removed by washing with 2 Â saline-sodium citrate buffer (SSC; 1 Â SSC¼0.015 M NaCl/0.0015 M sodium citrate) containing 14 mM b-mercaptoethanol (RT; 30 min), followed by incubation with 4 mg/ml ribonuclease in 0.5 M NaCl/0.05 M EDTA/0.05 M Tris-HCl (pH 7.5) for 1 h at 371C. High-stringency washes were carried out at 551C for 2 h in 1 Â SSC/50% formamide/0.8 mM bmercaptoethanol, and then at 681C for 1 h in 0.2 Â SSC/1.4 mM b-mercaptoethanol/0.5% sarkosyl. Slices were mounted onto Superfrost slides (Fisher Scientific) and dehydrated with ethanol and chloroform before autoradiography. Slides were exposed for 1-4 days to a Kodak X-AR film and then dipped in an Ilford K-5 emulsion. After 4 weeks, slides were developed with Kodak D19 developer, fixed and counterstained with Richardson's blue.
Results
Groups of mice (n¼25) were treated with clozapine, haloperidol or saline for 45 min, 7 h, 5 days, 12 days and 2 weeks. Poly(A) þ -enriched RNA from the striatum and frontal cortex were analyzed using TOGA s , an automated, systematic, PCR-based RNA display technique. Complete TOGA s analysis involves 256 different PCR reactions with a given restriction enzyme (MspI, in this case) performed on each RNA sample and divides PCR fragments from the 3 0 ends of mRNAs into 256 nonoverlapping pools. The fluorescent PCR products, each of which derives from a different mRNA in the starting population, are detected by capillary electrophoresis. Each peak whose amplitude corresponds to greater that one part in 10 6 of the input RNA is entered into an electronic database, which can be queried by proprietary software (for details, see Sutcliffe et al, 30 www.dgt.com). A representative PCR profile highlighting expression regulation by clozapine and haloperidol is shown in Figure 1 . Approximately 17 315 TOGA s cDNA products were detected and databased in the present study.
The database was queried electronically for TOGA s product amplitudes that differed in duplicate drug experiments by 1.6-fold or more in both the 12-day and 2-week drug-vs saline-treated samples (see 'Materials and methods' for further details). A total of 51 candidate cDNAs ('digital sequence tags', DSTs) were identified to be regulated by clozapine and/or haloperidol (drug effect; P¼0.0006 at 1.6-fold regulation). A total of 46 were found to be regulated by clozapine (23 upregulated and 23 downregulated) in the striatum and/or cortex and 38 by haloperidol (28 upregulated and 10 downregulated) in the striatum only. Out of the 51 DSTs in total, 13 were clozapine specific in their regulation, five were haloperidol specific and 33 were regulated by both drugs ( Table 1 ). The differential regulation of expression was also apparent in the striatum vs cortex for some of the DSTs. The expression patterns of the glutamate receptor g2 subunit, Neu17 and Neu136, were altered by clozapine only in the cortex and not the striatum, while the expression of ubiquitinconjugating enzyme E2R was increased by clozapine in the striatum, but decreased in the cortex ( Table 2) . Many of the DSTs had candidate identities predicted electronically by their TOGA s addresses. These identities were verified by extended specific primers as described previously. 30 For those DSTs that did not correspond to a species with a predicted identity, cDNA clones were isolated and their nucleotide sequences were determined. The sequences of these DSTs were blasted in the GenBank and mouse genome databases to determine the identity of the molecules. The identities of these candidate cDNA clones fell into several distinct classes, while 14 DSTs were additionally identified, which corresponded to presently unknown sequences (Table 2 ). This information reveals which systems or pathways may be affected by antipsychotic drug treatment and, possibly, which systems may be dysfunctional in psychiatric disorders.
To validate the TOGA s methodology, real-time PCR analysis was performed on selected cDNAs using the -8) , n-chimerin, P/Q-type calcium channel a1A subunit, lysophosphatidic acid (LPA) acyltransferase, Traf2-and Nck-interacting kinase-8 (TNIK-8), L1-like cell adhesion molecule, neural activity-related ring finger protein (NARF), calmodulin-dependent phosphodiesterase (PDE1B1) and four unidentified sequences, Clz40, Clz62, Neu13 and Neu44 (Figure 2 ). For all but two DSTs, NARF and Neu44, real-time PCR analysis confirmed the expression regulation for haloperidol ( Figure 2 ). mRNA expression was not detected on Northern blots for Neu44, the L1-like cell adhesion molecule and OSBPL-8.
We next investigated the CNS expression patterns of drug-regulated genes using in situ hybridization analysis. In untreated mouse brains, some mRNAs exhibited relatively ubiquitous expression patterns, while others exhibited considerable anatomical selectivity (Table 3) . Relatively abundant and ubiquitous expression patterns were detected for NARF, LPA acyltransferase, n-chimerin and TNIK-8, while Neu44 was ubiquitously expressed in low abundance (Table  3) . Striatal-predominant expression was detected for the mouse homolog of OSBPL-8 and PDE1B1, but mRNA expression was also detected in the cortex and hippocampus (Table 3, Figure 3 ). Clz40 displayed enriched expression in the nucleus accumbens and dentate gyrus over other brain regions, but also showed low-abundance ubiquitous hybridization signals (Table 3) . The novel species, Neu13, was detected in sparsely distributed individual cells, predominantly in the cortex, ventricular lining, thalamus and hippocampus (Table 3, Figure 3) .
The expression patterns of OSBPL-8 and Neu13 were further examined by in situ hybridization using brains of saline-, clozapine-and haloperidol-treated mice (n¼4 per drug pair). OSBPL-8 mRNA was found to be increased in the striatum and cortex by both clozapine and haloperidol treatment (Figure 3 ). This effect was evident primarily in the striatum, olfactory tubercle and cortex. In contrast, Neu13 exhibited an overall decreased expression in the brains of mice treated with either clozapine or haloperidol, being barely detectable in the brains of clozapine-treated mice (Figure 3) . The increase in the expression of apoD in drug-treated animals as detected by in situ hybridization has been demonstrated and discussed in our previous studies. 32 
Discussion
In this study, we utilized TOGA s to investigate changes in gene expression in mouse striatum and cortex induced by clozapine and haloperidol administration. We profiled expression patterns at five different time points of drug treatment (45 min, 7 h, 5 days, 12 days and 2 weeks), and, in this study, have focused on those genes regulated at the long-term time points (12 days and 2 weeks) compared to salinetreated controls. The expression of genes encoding proteins involved in diverse functions, including in neurotransmission, calcium homeostasis, signal transduction, oxidative stress, cell adhesion, Table 3 Anatomical distributions of mRNAs of clozapine-and haloperidol-regulated clones based on in situ hybridization analysis
In situ hybridization studies were performed using 35 S-labeled riboprobes on free-floating brain sections from control mice (see Materials and methods for details). Slices were exposed to autoradiographic film for 1-5 days and then dipped in silver emulsion and exposed for 4 weeks. The abundance of hybridization signals was based on the density of the signal from the autoradiographic data or by high-magnification examination of emulsion-dipped slides: þ, low abundance; þ þ, medium abundance; þ þ þ, high abundance; À, not detected. Figure 3 In situ hybridization analysis demonstrating increased OSBPL-8 mRNA expression and decreased Neu13 mRNA expression in mouse brain after clozapine and haloperidol administration. Free-floating coronal sections from mouse brains of saline and drug-treated mice were probed with an antisense 35 S-labeled OSBPL-8 and Neu13 riboprobes. NC, neocortex; CPu, caudate putamen; NAcc, nucleus accumbens; Hipp, hippocampus; Thal, thalamus; Hyp, hypothalamus. apoptosis and proteolysis, were found to be altered in the brains of both clozapine-and haloperidol-treated mice. Notable was the differential expression of genes whose products are associated with phospholipids/ fatty acid signaling and metabolism. These include the mouse homolog of OSBPL-8, n-chimerin, LPA acyltransferase, steroid dehydrogenase Ke6 and apoD (which we have already described in a previous study). 32 Oxysterols are 27-carbon products of cholesterol oxidation that display several biological activities, including cytotoxic effects, perturbation of membrane structure and function of membrane-associated proteins, as well as disturbance of cellular cholesterol homeostasis. 33, 34 Oxysterol-binding proteins are a family of eucaryotic intracellular lipid receptors that bind oxysterols and regulate cholesterol and lipid homeostasis. 34, 35 Our mouse sequence was found to be the homolog of the human OSBPL-8, whose function is not precisely known, 35 but likely functions in a manner similar to other family members. Interestingly, the oxysterol, 25-hydroxycholesterol, which is a potent regulator of cellular cholesterol homeostasis in mammalian cells, has been shown to elevate apoD levels in cultured astrocytes. 36 This provides a potential link towards a common function for these two drug-regulated genes.
N-chimerin (a1-chimerin) was originally identified as a 34-kDa protein highly expressed in the brain and then later defined as a member of a new family of 'nonprotein kinase C' phorbal ester/diacylglycerol (DAG) receptors. 37, 38 DAG is a lipid second messenger generated directly by the action of phospholipase C isozymes or indirectly via the activation of phospholipase D and subsequent release of phosphatidic acid (PA), a phospholipid signaling molecule. These DAG receptors act as GTPase accelerating proteins, which enhance cellular G-protein signal transduction. 38 We also confirmed the expression regulation of LPA acyltransferase, which catalyzes the conversion of LPA to PA. 39 LPA, another phospholipids signaling mediator, acts via a specific G-protein-coupled receptor (lysophospholipid receptors), several of which have been recently identified. 40, 41 Hence, n-chimerin and LPA acyltransferase appear to also function in a common pathway of lipid signal transduction. Interestingly, membrane lysophosphatidylcholine levels has been shown to be elevated in platelets of schizophrenic patients. 42 Antipsychotic drugs have previously been shown to alter phospholipid-related second messenger pathways, such as those involved in phosphatidylinositol (PI) hydrolysis, by blocking neurotransmitter receptor active sites. Chronic haloperidol, chlorpromazine and clozapine administration to rats has been shown to cause decreases in norepinephrine-and dopamineand serotonin-induced PI hydrolysis in rat brain. [43] [44] [45] [46] Many studies, however, have observed effects of antipsychotic drugs on pathways involving fatty acids, which may not be related to blockade of receptors. Clozapine administration has been shown to inhibit arachidonic acid-induced aggregation of rabbit platelets, suggesting an inhibition of the generation of prostaglandin endoperoxides or thromboxanes 47 and elevate arachidonic and docosahexaenoic acid levels in red cell membranes of schizophrenic patients. 48 Clozapine administration is also associated with other serum lipid abnormalities in psychiatric patients. 49 The final lipid-related molecule identified in our study, steroid dehydrogenase Ke6, has significant homology to mammalian 11 beta-hydroxysteroid dehydrogenases (11 beta-HSDs). These enzymes catalyze the interconversion of active glucocorticoids (cortisol and corticosterone) into their inactive 11-keto products (cortisone and 11-deoxycorticosterone). 50, 51 This is consistent with the fact that glucoregulatory abnormalities, including weight gain, have been associated with the use of antipsychotic medications. 49, 52, 53 Overall, these findings suggest that the antipsychotic drugs may exert their effects, beneficial or otherwise, by targeting pathways associated with lipid metabolism and homeostasis. This notion is consistent with a growing body of literature that has implicated abnormalities in various aspects of lipid metabolism, signal transduction, cholesterol and glucocorticoid homeostasis in psychiatric disorders. [54] [55] [56] [57] 58 In the current study, we also identified genes that are related to calcium signaling and homeostasis to be regulated by antipsychotic drug treatment. These include the P/Q-type calcium channel a1A subunit, the calcium/calmodulin-dependent PDE1B1 and two candidate genes, glutamate receptor g2 subunit and striatin, a calmodulin-binding protein 4. These findings are consistent with a recent study investigating global gene expression changes in response to drug treatment using cDNA microarray analysis, in which several genes involved in the regulation of intracellular calcium stores were recognized. 27 In this study, candidate genes were first identified in a microarray screen of genes regulated by acute clozapine treatment, and then additional in situ hybridization analyses were performed on selected genes to examine the expression levels in response to chronic clozapine and haloperidol treatment. 27 Increased expression patterns of visinin-like proteins, which belong to a family of intracellular calcium sensor proteins, chromogranin A, a calcium-binding protein enriched in large dense core vesicles, and calcineurin A, a calcium and calmodulin-dependent serinethreonine protein phosphatase, were observed in response to both clozapine and haloperidol. 27 Interestingly, microarray analysis of gene expression in schizophrenic brain tissue has identified an increased expression of calcineurin A in the prefrontal cortex of neuroleptic-medicated patients. 59 Since it is not possible to perform drug-induced gene expression analysis on human subjects, we employed a mouse model in this study. However, the mouse brain is comparatively different from primate brain, especially the frontal cortex.
Interspecies differences in the cortex exist in terms of the complexity of neuronal connectivity, the organization and elaboration of dopaminergic innervation, receptor subtype expression, neuropeptide colocalization and development processes. [60] [61] [62] The dynamics of dopamine release, uptake kinetics, regulation by firing frequency and presynaptic autoreceptor function in the human striatum, which consists of a distinct caudate nucleus and putamen, also differs considerably from rodent striatum. 63, 64 Hence, the pharmacological response in cortical or striatal sites to antipsychotic drugs may be different in primate brain than in mouse brain resulting in potentially different transcriptome profiles.
While microarray analysis has been a popular approach for the study of differentially expressed genes, its application has successfully identified relevant candidate genes in many disease and drug paradigms, TOGA s offers several advantages over presently used microarray methods. The first is sensitivity. Whereas microarrays have sensitivity that ranges from one part in 10 5 to one part in 10 4 , depending upon the nucleotide sequence and composition of each particular element in the array, TOGA s has a sensitivity of one part in 10 6 . We identified several transcripts of low abundance in the current study, such as the glutamate receptor g2 subunit and the Ca þ 2 channel a1A subunit, and many of which could not be detected by Northern blot analysis and might not have been detected by microarrays. Secondly, TOGA s is not limited by the current state of knowledge, which can restrict the focus of drug analyses, nor does it require a priori assumptions about the underlying mechanisms of drug action. In the current study, we identified molecules not previously associated with drug treatment, including those related to lipid signaling, proteolysis and cell adhesion. These genes would not have been identified using a candidate molecule approach. Finally, TOGA s can identify previously unidentified sequences (ESTs) and RNA splice variants and, importantly, it does not require genome annotation. We validated the expression regulation of four sequences in the current study, Clz40, Clz62, Neu13 and Neu44, which did not show homology to known nucleotide or protein sequences. Although it was not an issue in the present investigation, TOGA s requires only 20 ng of total input RNA, substantially less than hybridization-based methods. Other sequence-based global gene expression methods, including serial analysis of gene expression (SAGE) 65 and massively parallel signature sequencing (MPSS), 66 which rely on multiple short oligonucleotide sequences to identify unique mRNA transcripts, also share several advantageous properties with TOGA s . These include the identification of low abundant transcripts and previously unknown sequences. SAGE also only requires low amounts of starting material (50-500 ng mRNA). A major drawback of these techniques includes their expense, which limits their application to multiple samples, allowing only single expression dichotomies to be investigated. Unlike microarray techniques, these methods have not been widely used to study neuropsychiatric disorders; however, one study has used SAGE to identify interesting candidate genes associated with bipolar disorder. 67 High-throughput analyses have revealed complex gene expression patterns induced by antipsychotic drug treatment. With these emerging studies, we are beginning to gain an understanding about how drugs may be working to correct underlying abnormalities in psychiatric and other diseases that use antipsychotic drugs as part of their treatment regimen. Some of these molecules may represent new drug targets for improved therapeutics for these disorders and support the involvement of lipid pathways in the pathophysiology of schizophrenia and other psychiatric disorders.
